Infectious Disease News, April 2015
Roula Baroudi, MD; Edward Grace, PharmD; Marquetta Flaugher, PhD, ARNP
Alinia, the first thiazolide, was approved in 2002 by the FDA for the treatment of protozoal and helminthic infections. It was hypothesized that the drug may have possible antiviral activity by increasing the phosphorylation of double-stranded RNA-dependent protein kinase and the induction of eukaryotic-initiation of factor 2-alpha, which is an important factor in the innate immune response against hepatitis C infection.
Before the introduction of the direct-acting antiviral agents in 2011, treatment for HCV consisted of combination therapy using ribavirin (RBV) and pegylated interferon (PEG-IFN). Treatment therapy of nonresponders, relapsers or patients who were not candidates for combination therapy with RBV and PEG-IFN were often offered salvage therapy with experimental drugs in an attempt to suppress the HCV and thus, halt the development of hepatocellular carcinoma.